Anaptysbio, inc (ANAB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Revenue from Contract with Customer, Excluding Assessed Tax

23,000

8,000

5,000

10,000

5,000

5,000

8,000

3,000

10,000

10,000

9,754

12,968

11,818

16,684

0

0

0

Operating expenses:
Research and development

99,675

99,338

93,832

81,784

65,017

56,196

47,882

36,696

33,318

29,443

26,853

23,438

18,568

15,419

0

0

0

General and administrative

16,238

16,094

16,005

16,195

15,720

15,526

14,328

12,714

11,232

9,338

7,705

6,322

5,124

4,290

0

0

0

Total operating expenses

115,913

115,432

109,837

97,979

80,737

71,722

62,210

49,410

44,550

38,781

34,558

29,760

23,692

19,709

0

0

0

Loss from operations

-92,913

-107,432

-104,837

-87,979

-75,737

-66,722

-54,210

-46,410

-34,550

-28,781

-24,804

-16,792

-11,874

-3,025

0

0

0

Other income (expense), net:
Interest expense

721

1,041

1,206

1,366

1,521

1,652

1,743

1,795

1,798

1,775

1,430

1,094

771

458

0

0

0

Change in fair value of liability for preferred stock warrants

-

-

-

-

-

-

-

-

-

1,366

2,457

2,504

2,501

756

0

0

0

Interest income

9,893

10,984

11,536

10,148

8,488

6,685

4,713

3,702

2,686

1,623

0

0

0

-

-

-

-

Other income, net

88

1

118

-66

-89

-159

-283

-152

-59

229

16

48

91

-147

0

0

0

Total other income (expense), net

9,260

9,944

10,448

8,716

6,878

4,874

2,687

1,755

829

-1,289

-2,983

-3,020

-2,932

-1,234

0

0

0

Loss before income taxes

-83,653

-97,488

-94,389

-79,263

-68,859

-61,848

0

0

0

-

-

-

-

-

-

-

-

Provision for income taxes

-133

-152

-322

-271

-211

-192

0

0

0

-

-

-

-

-

-

-

-

Net loss

-83,520

-97,336

-94,067

-78,992

-68,648

-61,656

-51,523

-44,655

-33,721

-30,070

-27,787

-19,812

-14,806

-4,259

0

0

0

Other comprehensive income (loss):
Net income attributed to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Net loss attributed to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Unrealized income on available for sale securities, net of tax of $0 and $115, respectively

941

561

1,447

1,677

1,431

203

-924

-1,044

-1,214

-426

-43

-59

-13

0

0

0

0

Other comprehensive income (loss), net of tax

-

-

-

-

-

-

-

-

-

-

-43

-59

-13

0

0

0

0

Comprehensive loss

-82,579

-96,775

-92,620

-77,315

-67,217

-61,453

-52,447

-45,699

-34,935

-30,496

-25,689

-17,730

-14,819

-4,259

0

0

0

Net loss per common share:
Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.42

0.07

-

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.42

0.05

-

Basic and diluted (in dollars per share)

-0.30

-0.74

-1.15

-0.89

-0.82

-0.64

-0.66

-0.57

-0.63

-0.19

-0.45

-0.13

-0.75

-

-

-

-0.34

Weighted-average number of shares outstanding:
Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,636

2,635

-

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,636

3,498

-

Basic and diluted (in shares)

27,264

27,171

27,058

27,026

26,981

26,813

24,146

23,932

23,801

23,180

20,382

20,271

15,295

-

-

-

2,629